In Vitro Activity of Ceftaroline, Linezolid, and Tigecycline against Staphylococcus aureus and Streptococcus pneumoniae by Infection Site in the Africa/Middle East Region, 2014-17

In Vitro Activity of Ceftaroline, Linezolid, and Tigecycline against Staphylococcus aureus and Streptococcus pneumoniae by Infection Site in the Africa/Middle East Region, 2014-17

Bibliographic Details
Main Authors:	I Morrissey, A Johnson, M Hackel, G Stone, Dowzicky M, D Sahm
Format:	Article
Language:	English
Published:	Elsevier 2020-02-01
Series:	Journal of Infection and Public Health
Online Access:	http://www.sciencedirect.com/science/article/pii/S1876034120300794

Similar Items

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
by: Antoní Torres, et al.
Published: (2023-10-01)

Susceptibility of Clinical Isolates of Staphylococcus aureus to Ceftaroline
by: Harsha Sreedharan, et al.
Published: (2021-01-01)

Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital
by: Apurwa Karki, et al.
Published: (2017-10-01)

Comparison of Etest and broth microdilution for evaluating the susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to ceftaroline and of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa to ceftazidime/avibactam
by: Yu-Tsung Huang, et al.
Published: (2021-09-01)

Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus
by: Cheng-En Tsai, et al.
Published: (2022-09-01)

Pneumonia Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: Vancomycin or Linezolid?
by: Ye Tian, et al.
Published: (2018-01-01)

The Use of Linezolid in the Treatment of Ventilator-Associated Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus
by: Büşra ERGÜT SEZER, et al.
Published: (2009-03-01)

Effects of Subinhibitory Concentrations of Ceftaroline on Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms.
by: María Lázaro-Díez, et al.
Published: (2016-01-01)

Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
by: Stefania Stefani, et al.
Published: (2016-11-01)

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin
by: Estes Kerry S, et al.
Published: (2010-11-01)

Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial
by: Anna Giammanco, et al.
Published: (2017-02-01)

The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase–negative staphylococci strains: a systematic review and meta-analysis
by: Aref Shariati, et al.
Published: (2020-04-01)

Sub-Inhibitory Concentrations of Oxacillin, but Not Clindamycin, Linezolid, or Tigecycline, Decrease Staphylococcal Phenol-Soluble Modulin Expression in Community-Acquired Methicillin-Resistant Staphylococcus aureus
by: Elisabeth Hodille, et al.
Published: (2022-02-01)

Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of China
by: Lesher B, et al.
Published: (2016-03-01)

10: IN VITRO ACTIVITIES OF CEFTAROLINE AND COMPARATOR AGENTS AGAINST BACTERIAL PATHOGENS COLLECTED FROM PATIENTS WITH SKINAND SOFT TISSUE INFECTIONS IN THE ASIA/PACIFIC REGION FROM THE ATLAS SURVEILLANCE PROGRAM 2020
by: Meredith Hackel, Dr., et al.
Published: (2022-11-01)

8: IN VITRO ACTIVITIES OF CEFTAROLINE AND COMPARATOR AGENTS AGAINST BACTERIAL PATHOGENS FREQUENTLY CAUSING COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS IN PATIENTS FROM ASIA/PACIFIC: ATLAS SURVEILLANCE PROGRAM 2020
by: Meredith Hackel, Dr., et al.
Published: (2022-11-01)

In vitro activity of ceftaroline: A novel antibiotic against methicillin-resistant Staphylococcus aureus
by: Vaishali Gaikwad, et al.
Published: (2016-01-01)

In Vitro Activity of Aztreonam-avibactam and Ceftazidime-avibactam against Pseudomonas aeruginosa Collected in a Global Surveillance Program in the Africa/Middle East, 2014–2017
by: I Morrissey, et al.
Published: (2020-02-01)

Ceftaroline-related acute eosinophilic pneumonia
by: Zaw Min, et al.
Published: (2021-01-01)

Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - comparison of pharmacology and clinical efficacy
by: Pletz Mathias W, et al.
Published: (2010-11-01)

Evaluation of in vitro activity of ceftaroline on methicillin resistant Staphylococcus aureus blood isolates from Iran
by: Negin Abdizadeh, et al.
Published: (2021-08-01)

Treatment of Staphylococcus aureus keratitis with 0.2% topical linezolid
by: Lincoln Lavado Landeo
Published: (2015-09-01)

Ceftaroline versus vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in an experimental MRSA meningitis model
by: Sinan Mermer, et al.
Published: (2020-09-01)

Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study
by: Samia Arshad, et al.
Published: (2017-04-01)

Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010–2019)
by: Helio S. Sader, et al.
Published: (2021-01-01)

Antimicrobial Susceptibility Profile of Healthcare-Associated Methicillin Resistant Staphylococcus aureus with Special Reference to Vancomycin and Ceftaroline
by: S. M, et al.
Published: (2022-03-01)

Parallel evolution of linezolid-resistant Staphylococcus aureus in patients with cystic fibrosis
by: Nicholas J. Pitcher, et al.
Published: (2023-10-01)

Structural basis for linezolid binding site rearrangement in the Staphylococcus aureus ribosome
by: Tofayel Ahmed, et al.
Published: (2019)

Economic evaluation of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
by: Tazio Vanni

Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus
by: Adão R. L. Machado, et al.

Characterizing the role of porin mutations in susceptibility of beta lactamase producing Klebsiella pneumoniae isolates to ceftaroline and ceftaroline-avibactam
by: Ali Khalid, et al.
Published: (2020-04-01)

The Role of ArlRS and VraSR in Regulating Ceftaroline Hypersusceptibility in Methicillin-Resistant <i>Staphylococcus aureus</i>
by: Maite Villanueva, et al.
Published: (2021-07-01)

Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals
by: Wadha Alfouzan, et al.
Published: (2020-10-01)

Corrigendum: Genome-Wide Association Studies for the Detection of Genetic Variants Associated With Daptomycin and Ceftaroline Resistance in Staphylococcus aureus
by: Robert E. Weber, et al.
Published: (2021-04-01)

Tigecycline Resistance-Associated Mutations in the MepA Efflux Pump in Staphylococcus aureus
by: Honghao Huang, et al.
Published: (2023-08-01)

In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015–2018
by: James A. Karlowsky, et al.
Published: (2021-03-01)

In-vitro Susceptibility of Linezolid and Teicoplanin in Methicillin-resistant Staphylococcus aureus by E-test
by: Thammina Meher Srisai Sudhavani, et al.
Published: (2023-01-01)

Linezolid-resistance Staphylococcus aureus – Prevalence, Emerging Resistance Mechanisms, Challenges and Perspectives
by: Hassan Rafique, et al.
Published: (2022-09-01)

Bactericidal Effect of Photodynamic Therapy, Alone or in Combination with Mupirocin or Linezolid, on Staphylococcus aureus
by: Vanesa Pérez-Laguna, et al.
Published: (2017-05-01)

In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
by: Gustavo Enck Sambrano, et al.
Published: (2014-08-01)